Wave life sciences reports second quarter 2020 financial results and provides business update

Wave life sciences reports second quarter 2020 financial results and provides business update.c9orf72 and snp3 clinical trial applications on track to be submitted in 4q 2020.as of june 30, 2020, wave had $94.1 million in cash and cash equivalents.wave life sciences - expects existing cash & cash equivalents with expected & committed cash, to fund operating and capex requirements into q4 of 2021.qtrly loss per share $1.15.q2 earnings per share view $-0.97 -- refinitiv ibes data.qtrly revenue $3.0 million versus $7.6 million.q2 revenue view $5.7 million -- refinitiv ibes data.
WVE Ratings Summary
WVE Quant Ranking